Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Justdosomeddon Aug 15, 2022 2:22pm
118 Views
Post# 34897125

Natural Consolidation After Last Week's Run

Natural Consolidation After Last Week's Run
$AGN.C is seeing some consolidation after last week’s big run as some investors take profits on their gains. Their model of using approved, safe, and well-established drugs for undiscovered uses has already shown great promise over the past few months as their research trials continue to move forward. Recent results from the phase 2 Ifenprodil IPF/Chronic Cough study found positive results for both treatments. With only 2 existing IPF treatments costing tens of thousands of dollars, $AGN.C has considerable market potential once they reach approval.
 
Not only do they have a potential drug for IPF/Chronic Cough, but $AGN.C is also researching into the use of DMT microdoses to help stroke victims with preclinical work concluded and evidence to support that DMT is effective in promoting neurogenesis and synaptic growth. Additionally, they're developing reprinast for treating chronic kidney disease, which has shown to decrease fibrosis significantly.
 
Considering that their drug development targets multiple multi-billion dollar markets, there's significant room for upside, especially with the recently placed $25 price target. Keep an eye out for the film phase 2a Ifenprodil IPF results in Q3, phase 1 studies for Repirinast, DMT, and Ifenprodil (for cancer treatments) in Q4, and phase 2b of Ifenprodil for IPF during mid-2023. Only an $8M valuation here, and looking at all these potential catalysts, definitely keep an eye out for future developments.
<< Previous
Bullboard Posts
Next >>